Tempus AI, Inc. (NASDAQ:TEM) Receives $61.18 Consensus Target Price from Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been assigned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $61.18.

Several research analysts recently commented on TEM shares. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Bank of America boosted their target price on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. TD Cowen reiterated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Finally, Morgan Stanley boosted their price target on Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th.

Tempus AI Stock Up 4.5 %

Shares of Tempus AI stock opened at $42.12 on Thursday. The company has a 50-day simple moving average of $56.19 and a two-hundred day simple moving average of $50.92. Tempus AI has a one year low of $22.89 and a one year high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 170,720 shares of Tempus AI stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total value of $6,052,024.00. Following the completion of the transaction, the insider now owns 15,993,729 shares of the company’s stock, valued at approximately $566,977,693.05. The trade was a 1.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 3,000 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the sale, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. The trade was a 10.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,581,969 shares of company stock worth $316,538,582 over the last quarter.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. Operose Advisors LLC purchased a new stake in shares of Tempus AI during the fourth quarter worth about $25,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI in the 4th quarter worth about $34,000. Prestige Wealth Management Group LLC increased its stake in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at approximately $49,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after acquiring an additional 1,108 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.